May 10, 2024 5:22pm

Sentiment is yet again not moving in the right direction

The Harvard Apparatus RT (OTCQB: HRGN) Chronicles: Ponzi Scheme, a Madoff look-a-life or just a Communist China rip-off? Even lipstick won't help this Pig., stil a going concern and all but broke.

As I had stated, “let’s not forget about volatility”

A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio’s defense or offence.

Never leave an investor uninformed! A trusted source of factual reporting!

The week in review …

 

The present and future value of RegMed Investors (RMi) NEWS sheds light on the stem, cell and gene therapy sector’s risks to share pricing and the sector’s upside acrobatics and potential downslides.

I write this blog/newsletter about – facts in evidence! 

 

Friday: The Dow closed UP +125.08 points or +0.32%, the S&P closed UP +8.60 points or +0.16% while the Nasdaq closed DOWN -5.40 points or -0.03

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes were mixed with a strong earnings season, as well as some softer labor data.

During this week, the Dow was up +2.16%, the S&P +1.85% and the Nasdaq +1.14%.

Economic Data Docket: Consumer sentiment data reflected a big uptick in inflation expectations, throwing some cold water on the market. The preliminary May reading for the University of Michigan’s consumer sentiment index came in at 67.4, far below a Dow Jones estimate of 76 and marking its lowest reading in about six months.

 

RegMed Investors (RMi) Research Note: Q1/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes … https://www.regmedinvestors.com/articles/13441   

RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Advance/Decline (A/D) Line:

  • Friday’s advance/decline line at the open was negative with 16 incliner, 17 decliners and 2 flats; ending with a negative close of 10 incliners, 23 decliners and 2 flats
  • Thursday’s advance/decline line at the open was positive with 20 incliner, 13 decliners and 2 flats; ending with a positive close of 21 incliners, 11 decliners and 3 flats
  • Wednesday’s advance/decline line at the open was negative with 4 incliner, 28 decliners and 3 flats; ending with a negative close of 5 incliners, 27 decliners and 3 flats
  • Tuesday’s advance/decline line at the open was negative with 10 incliner, 22 decliners and 3 flats; ending with a negative close of 16 incliners, 18 decliners and 1 flat
  • Monday’s advance/decline line at the open was positive with 217 incliner, 16 decliners and 2 flats; ending with a positive close of 17 incliners, 15 decliners and 3 flats

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q2/24: 5 positive and 3 negative closes

  • April; 16 negative and 6 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB was down -0.01% and the XBI was down -0.94%
  • Thursday, the IBB was up +0.63% and the XBI was down -0.15%
  • Wednesday, the IBB was down -0.69% and the XBI was down -1.46%
  • Tuesday, the IBB was up +0.20% and the XBI was down -0.17%
  • Monday, the IBB was up +0.05% and the XBI was up +0.67%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -0.14 point or -1.10% at 12.55
  • Thursday was down -0.30 point or -2.31% at 12.70
  • Wednesday was down -0.23 point or -1.74% at 13.00
  • Tuesday was down -0.25 point or -1.85% at 13.24
  • Monday was down -0.01 point or -0.07% at 13.48

 

Friday’s Closing Down (10 of 23):

  • CRISPR Therapeutics (CRSP -$2.38 after Thursday’s +$0.26 after Wednesday’s -$2.24 after Tuesday’s -$1.53 and Monday’s +$1.17)
  • Blueprint Medicine (BPMC -$1.64 after Thursday’s -$0.44, Wednesday’s +$0.23, Tuesday’s +$2.30 and Monday’s -$0.94)
  • Beam Therapeutics (BEAM -$1.28 after Thursday’s +$0.30),
  • Agenus (AGEN -$1.23 after Thursday’s +$0.25, Wednesday’s -$0.54, Tuesday’s -$0.94 and Monday’s -$0.12)
  • Alnylam Pharmaceuticals (ALNY -$0.90 after Thursday’s -$0.92, Wednesday’s +$2.04, Tuesday’s +$3.11 and Monday’s -$1.11),
  • Vericel (VCEL -$0.55 after Thursday’s +$0.96, Wednesday’s -$1.83, Tuesday’s +$2.58 and Monday’s -$0.89
  • Sage Therapeutics (SAGE -$0.44 after Thursday’s -$0.05, Wednesday’s -$0.59, Tuesday’s -$0.27 and Monday’s -$0.69)
  • Intellia Therapeutics (NTLA -$0.40 after Thursday’s +$1.86, Wednesday’s -$0.88, Tuesday’s +$0.16 and Monday’s +$0.12)
  • Ionis Pharmaceuticals (IONS -$0.39 after Thursday’s -$0.69, Wednesday’s -$0.77, Tuesday’s -$1.35 and Monday’s +$0.31),
  • Verve Therapeutics (VERV -$0.35 after Thursday’s +$0.28),

Flat (2):

  • Bellicum Pharmaceuticals (BLCM) – dropped
  • Voyager Therapeutics (VYGR)

Friday’s Closing Up (10 of 10):

  • BioLife Solutions (BLFS +$1.53),
  • Lenz Therapeutics (LENZ +$0.33 after Thursday’s -$0.78),
  • MiMedx (MDXG +$0.21),
  • Mesoblast (MESO +$0.19),
  • Fate Therapeutics (FATE +$0.18 after Thursday’s +$0.20),
  • Harvard Apparatus RT (OTCQB: HRGN +$0.07),
  • Solid Biosciences (SLDB +$0.05),
  • Sangamo therapeutics (SGMO +$0.038),
  • Compass Therapeutics (CMPX +$0.01),
  • Homology Medicine (FIXX +$0.0071),

 

Q2/24 – May

  • Friday closed negative with 10 incliners, 23 decliners and 2 flats
  • Thursday closed positive with 21 incliners, 11 decliners and 3 flats
  • Wednesday closed negative with 5 incliners, 27 decliners and 3 flats
  • Tuesday closed negative with 16 incliners, 18 decliners and 1 flat
  • (5/6) Monday closed positive with 17 incliners, 15 decliners and 3 flats

 

The BOTTOM LINE:  a long week of earnings …

As I have written, “this week continues the Q1 financial performance elements of cell and gene therapy companies that sheds light on depreciated share value.”

Reporting today and share pricing: https://www.regmedinvestors.com/articles/11628   

Friday:

  • Prime Medicine (PRME) Q1 loss, missed EPS and revenue estimates

Thursday:

  • BioLife Solutions (BLFS) Q1 loss, miss revenue
  • Fate Therapeutics (FATE) Q1 loss miss revenue
  • Sangamo Therapeutics (SGMO) Q1 loss, miss revenue
  • Adverum Biotechnologies (ADVM) Q1 loss, 0 revenue
  • Intellia Therapeutics (NTLA): Q1 loss, EPS miss as revenue surpasses
  • bluebird bio (BLUE): Q1 loss, delayed due to current and past restatements

Wednesday

  • CRBU: Q1 loss, misses revenue and EPS estimate
  • VCEL: Q1 loss, surprise revenue up
  • VERV: Q1 loss, tops revenue and EPS estimates
  • EDIT: Q1 loss, revenue miss

Other Earnings to date:

  • RARE: Q1 loss
  • SAGE: Q1 loss
  • MDXG: Q1 loss
  • AXGN: Q1 loss
  • BPMC: net income
  • BEAM: Q1 loss, no revenue
  • IONS: Q1 loss, misses revenue and EPS estimate
  • AGEN: Q1 loss, misses revenue and EPS estimate
  • ALNY:  Q1 loss, tops revenue estimate and narrow miss on EPS
  • AXGN: Q1 loss, lags revenue estimates
  • BPMC: Q1 net incomes, surpasses revenue estimates

 

The top three (3) performing in the session:  

  • Friday: BioLife Solutions (BLFS), Lenz Therapeutics (LENZ) and MiMedx (MDXG)
  • Thursday: Intellia Therapeutics (NTLA), Vericel (VCEL) and Editas Medicine (EDIT)
  • Wednesday: Blueprint Medicine (BPMC), uniQure NV (QURE) and Brainstorm Cell Therapeutics (BCLI)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Blueprint Medicine (BPMC)
  • Monday: CRISPR Therapeutics (CRSP), Mesoblast (MESO) and Cellectis SA (CLLS)

The worst three (3) in the session:

  • Friday: CRISPR Therapeutics (CRSP), Blueprint Medicine (BPMC) and Beam Therapeutics (BEAM)
  • Thursday: Regenxbio (RGNX), Alnylam Pharmaceuticals (ALNY) and Lenz Therapeutics (LENZ)
  • Wednesday: Vericel (VCEL), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY),
  • Tuesday: CRISPR Therapeutics (CRSP), Ultragenyx Pharmaceuticals and Ionis Pharmaceuticals (IONS)
  • Monday: Alnylam Pharmaceuticals (ALNY), Blueprint Medicine (BPMC) and Vericel (VCEL

 

BEWARE… How MANY TIMES AM I RIGHT … MORE than MOST!!

The Harvard Apparatus RT (OTC QB HRGN) Chronicles: shows how the “pimp/pump and promote” share pricing works with WHAT news for so long …my treatise is VALIDATED!

Yet a further SCREW-JOB for early and present investors ...

April closes:

  • 5 ups, 5 downs and 11 flats

May:

  • Friday closed up +$0.07 with 2,254 share traded
  • Thursday closed flat with 0 shares traded
  • Wednesday closed flat with 0 shares traded
  • Tuesday closed down -$0.21 with 478 shares traded
  • (5/6) Monday closed flat with 45 shares traded
  • Friday, closed up +$0.02 with 165 shares traded
  • Thursday, closed up +$0.05 with 1,444 shares traded
  • (5/1) Wednesday closed flat 0 shares traded

Question, has its major shareholder and landlord, Harvard Bioscience (HBIO) in the midst of a lay-off; been left holding a depreciating “bag” of shares (5% or 697,112 shares – SC 13G/A filing) from its $4 M share of the wrongful death lawsuit settlement having been issued 4,000 shares of series E 8% convertible Preferred stock at a price of $1,000 per share to satisfy the indemnification obligations (10-K)? 

  • How will HBIO protect itself and its asset/balance sheet when and who will NOT finance this OTCQB: HRGN pig with this its lipstick and lingering odor?

Did you notice how it barely trades unless volume is being “pumped.”  This question needs to be answered as HRGN is desperate to finance by any means as past Chinese private placement investors must be feeling … WHAT … TAKEN to the cleaners?

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.